Table 5.
Impacts of clinicopathologic features on relapse during maintenance therapy in 47 APL patients receiving ATRA+IDA as an induction regimen
| Clinicopathologic parameters | Outcome
|
P-value | |
|---|---|---|---|
| Remission | Relapse | ||
| Sex | 0.295 | ||
| Male | 20 | 5 | |
| Female | 20 | 2 | |
| Age (years) | 0.727 | ||
| ≤40 | 20 | 3 | |
| >40 | 20 | 4 | |
| WBC count (×109/L) | 0.492 | ||
| ≤5 | 33 | 5 | |
| >5 | 7 | 2 | |
| Platelet count (×109/L) | 0.331 | ||
| ≤40 | 27 | 6 | |
| >40 | 13 | 1 | |
| Hemoglobin (g/L) | 0.086 | ||
| <100 | 30 | 3 | |
| ≥100 | 10 | 4 | |
| Maintenance regimens | 0.007 | ||
| ATRA+As2O3 | 22 | 0 | |
| ATRA+chemotherapy | 18 | 7 | |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.